COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 3 FDA records to the applicant name Freenome, LLC. It includes 1 original PMA approval. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 24, 2026 to Oct 27, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code PHP appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P250029, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: Bldg. 1, 3300 Marina Blvd., Brisbane, CA, 94005. Recorded on P250029/S003, decision dated Oct 27, 2026.
Device categories in this collection
System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection.
Changes described in PMA records
The FDA record for P250029/S003 describes a 30-day notice supplement to PMA P250029 for SimpleScreen CRC, submitted by Freenome, LLC. The stated purpose is approval of supplier reagent manufacturing and Quality Control changes, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The device category is listed as a system for colorectal neoplasia DNA methylation and hemoglobin detection.
The identifier establishes this as a supplement to an existing PMA, not an approval of the whole SimpleScreen CRC system. The source gives only the purpose statement for the supplier reagent manufacturing and quality control changes; it does not identify which reagent, supplier, or specific quality control parameters changed, nor does it provide data on safety or clinical performance. Those details are absent from the supplied record.
Regulatory and clinical conclusions beyond this descriptive paraphrase would go beyond the source. The notice's reported purpose should not be read as independent evidence of analytical validity, safety, or clinical effectiveness.
FDA approval-order wording
approval of supplier reagent manufacturing and Quality Control changes.
Oct 27, 2026 · 30-Day NoticeFDA’s recorded scope: changes in a supplier manufacturing processes for critical reagents
Aug 26, 2026 · 30-Day NoticeFDA’s recorded scope: The SimpleScreen CRC test is a qualitative, in vitro diagnostic test intended to detect molecular signals associated with colorectal cancer. SimpleScreen CRC utilizes circulating cell-free DNA from plasma of peripheral whole blood collected in the SimpleScreen CRC blood collection kit.SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
Jul 24, 2026Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.